Clinical trial phase 1 study in 32 pre-menopausal women without sexual dysfunction, in which the protein peptide was shown to be safe and well tolerated. A secondary endpoint in this study was the assessment of Bremelanotide's effect on vaginal blood ?ow. Results showed a signi?cant difference in the increase in vaginal blood ?ow in subjects treated with Bremelanotide versus placebo.
A Phase 2A pilot clinical study evaluating Bremelanotide in 18 pre-menopausal women diagnosed with FSD has also been completed with favorable results.
Key Clinical Findings from Phase 2A Study]patients receiving Bremelanotide reported increases in their levels of sexual desire and genital arousal compared to placebo correlation found between sexual desire and genital arousal in patients receiving Bremelanotide side effects were mild, including]nausea
headache
nasal congestion
A Phase 2 at-home study of Bremelanotide in FSD patients begins soon, new data to follow!
Bremelanotide: an overview of preclinical CNS effects on female sexual function
2007
Abstract
INTRODUCTION]
AIM]
MAIN OUTCOME MEASURES]
METHODS]
RESULTS]
CONCLUSIONS: To the extent that solicitations indicate the desire of female rats to engage in sexual activity, bremelanotide appears to possess the behavioral, pharmacological, and neuroanatomical specificity required of a drug in the treatment of hypoactive sexual desire disorders.
Reply With Quote